Irish General Practice Study of Acetylcysteine (Fabrol) in Chronic Bronchitis

Tattersall, Andrea; Bridgman, K M; Huitson, A.

doi:10.1177/030006058401200206

Cited by 7 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tattersall et al, in an open clinical trial including 1,392 patients demonstrated the efficacy of NAC at a dose of 600 mg/day in reducing the viscosity of expectorations, promoting expectoration and reducing the severity of cough. After 2 months of treatment with NAC, the viscosity of expectorations improved in 80% of cases, the nature of the expectorations improved in 59%, difficulty in expectorating improved in 74% and the severity of cough improved in 71% [13].…”

Section: Effect Of Nac On Quality Of Lifementioning

confidence: 99%

N-Acetyl Cysteine in treatment of COPD

Aleemuddin¹,

Fatima²,

Maqbool³

et al. 2020

IJIRM

View full text Add to dashboard Cite

In COPD excess expectoration secondary to tracheobronchial secretions contributes to symptoms, airflow obstruction and is diagnostic criterion. It also causes increased mortality, risk of hospitalizations and accelerated decline in FEV1. N-acetylcysteine (NAC) helps in liquefying mucus and DNA (via disruption of disulfide bonds) and has antioxidant effects. Aims: Evaluate add-on effect of NAC on clinical-physiological parameters in COPD patients treated according to GOLD guidelines. Material and Methods: Single labeled, randomized, parallel group prospective Observational study. In 120 stable COPD patients Modified medical research council (MMRC) dyspnoea score, COPD Assessment test (CAT score), number of exacerbations and hospitalizations in the last year were recorded and were randomized into 2 groups of 60 each. Group A received NAC 600mg twice daily along with standard treatment. Group B received standard treatment only. Mean and Standard Deviation was compared between groups using unpaired t-test. After 1 year, changes in above parameters were reassessed. Statistical Analysis: Unpaired t-test and chi square test were used. Statistical significance was set at <0.05 level. Results: MMRC score reduced from 3.37 study group) to 2.91, difference being -0.46, and in control from 3.37 to 1.18, difference of -0.22 and p value of p<.05. CAT score reduced more in test group (-4.4) than control group (-3.1), p=.02. Out of 40 exacerbations, 14 (35%) occurred in test and 26 (65%) in control group, reduction of 30% and p=0.01. Out of 28 hospitalizations 10 (36%) test group 18 (64%) control group. i.e. a reduction of 28% and p=0.06. Conclusions: Use of N-Acetyl Cysteine, 600mg twice daily along with standard treatment can bring clinically significant change in CAT Score and frequency of exacerbations but not in MMRC score and hospitalizations.

show abstract

Section: Effect Of Nac On Quality Of Lifementioning

confidence: 99%

N-Acetyl Cysteine in treatment of COPD

Aleemuddin¹,

Fatima²,

Maqbool³

et al. 2020

IJIRM

View full text Add to dashboard Cite

show abstract

“…Dyspnoea, on the other hand, may reflect more comprehensive information than airway obstruction in patients with COPD and should be taken into account while evaluating the successful treatment. NAC was reported to decrease the dyspnoea in COPD patients in comparison with placebo during the long-term treatment (Aylward et al 1980; Tattersall et al 1984). This may be partly caused by the mucolytic effects of NAC leading to increase in the sputum volume and pourability.…”

Section: Patient-focused Perspectivesmentioning

confidence: 99%

Role of N-acetylcysteine in the management of COPD

Sadowska

Verbraecken²,

Darquennes³

et al. 2006

International Journal of COPD

View full text Add to dashboard Cite

The importance of the underlying local and systemic oxidative stress and inflammation in chronic obstructive pulmonary disease (COPD) has long been established. In view of the lack of therapy that might inhibit the progress of the disease, there is an urgent need for a successful therapeutic approach that, through affecting the pathological processes, will influence the subsequent issues in COPD management such as lung function, airway clearance, dyspnoea, exacerbation, and quality of life. N-acetylcysteine (NAC) is a mucolytic and antioxidant drug that may also influence several inflammatory pathways. It provides the sulfhydryl groups and acts both as a precursor of reduced glutathione and as a direct reactive oxygen species (ROS) scavenger, hence regulating the redox status in the cells. The changed redox status may, in turn, influence the inflammation-controlling pathways. Moreover, as a mucolytic drug, it may, by means of decreasing viscosity of the sputum, clean the bronchi leading to a decrease in dyspnoea and improved lung function. Nevertheless, as successful as it is in the in vitro studies and in vivo studies with high dosage, its actions at the dosages used in COPD management are debatable. It seems to influence exacerbation rate and limit the number of hospitalization days, however, with little or no influence on the lung function parameters. Despite these considerations and in view of the present lack of effective therapies to inhibit disease progression in COPD, NAC and its derivatives with their multiple molecular modes of action remain promising medication once doses and route of administration are optimized.

show abstract

The Clinical Use of N-Acetylcysteine in Other Medical Disorders

Frye

2018

The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine

View full text Add to dashboard Cite

Irish General Practice Study of Acetylcysteine (Fabrol) in Chronic Bronchitis

Cited by 7 publications

References 3 publications

N-Acetyl Cysteine in treatment of COPD

N-Acetyl Cysteine in treatment of COPD

Role of N-acetylcysteine in the management of COPD

The Clinical Use of N-Acetylcysteine in Other Medical Disorders

Contact Info

Product

Resources

About